Long-term consequences of perinatal fatty acid amino hydrolase inhibition

British Journal of Pharmacology

Volumn 171, Issue 6, 2014, Pages 1420-1434

  Wu, Chia Shan ^a   Morgan, Daniel ^b   Jew, Chris P ^a   Haskins, Chris ^b   Andrews, Mary Jeanette ^b   Leishman, Emma ^b   Spencer, Corinne M ^a   Czyzyk, Traci ^b   Bradshaw, Heather ^b   MacKie, Ken ^b   Lu, Hui Chen ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

Acyl amide; cannabinoid; fatty acid amino hydrolase; neurodevelopment; prenatal exposure

Indexed keywords

ANANDAMIDE; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; FATTY ACID AMIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; BEHAVIOR DISORDER; BRAIN DEVELOPMENT; CONTROLLED STUDY; DEPRESSION; DRUG SAFETY; ENZYME INHIBITION; FEMALE; MALE; MASS SPECTROMETRY; MEMORY DISORDER; MOTOR COORDINATION; MOTOR PERFORMANCE; MOUSE; NERVE GROWTH; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PERINATAL DRUG EXPOSURE; PLACE PREFERENCE; PRIORITY JOURNAL; SENSORY GATING; WEIGHT GAIN; WORKING MEMORY;

AMIDOHYDROLASES; ANIMALS; BEHAVIOR, ANIMAL; BENZAMIDES; CARBAMATES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; MICE; MICE, INBRED ICR; PREGNANCY;

EID: 84895741693     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12500     Document Type: Article

References (72)

1. Aguado T, Monory K, Palazuelos J, Stella N, Cravatt B, Lutz B, et al. (2005). The endocannabinoid system drives neural progenitor proliferation. FASEB J 19: 1704-1706. (Pubitemid 41429536)
2. Ahn K, Johnson DS, Fitzgerald LR, Liimatta M, Arendse A, Stevenson T, et al. (2007). Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity. Biochemistry 46: 13019-13030. (Pubitemid 350086220)
3. Ahn K, Johnson DS, Cravatt BF, (2009). Fatty acid amide hydrolase as a potential therapeutic target for the treatment of pain and CNS disorders. Expert Opin Drug Discov 4: 763-784.
4. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Catterall WA, Spedding M, Peters JA, Harmar AJ, and CGTP Collaborators (2013). The Concise Guide to PHARMACOLOGY 2013/14: Overview. Br J Pharmacol 170: 1449-1867.
5. Bortolato M, Mangieri RA, Fu J, Kim JH, Arguello O, Duranti A, et al. (2007). Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress. Biol Psychiatry 62: 1103-1110. (Pubitemid 350029716)
6. Bradshaw HB, Rimmerman N, Krey JF, Walker JM, (2006). Sex and hormonal cycle differences in rat brain levels of pain-related cannabimimetic lipid mediators. Am J Physiol Regul Integr Comp Physiol 291: R349-R358. (Pubitemid 44035641)
7. Bradshaw HB, Rimmerman N, Hu SS, Benton VM, Stuart JM, Masuda K, et al. (2009). The endocannabinoid anandamide is a precursor for the signaling lipid N-arachidonoyl glycine by two distinct pathways. BMC Biochem 10: 14.
8. Campolongo P, Trezza V, Cassano T, Gaetani S, Morgese MG, Ubaldi M, et al. (2007). Perinatal exposure to delta-9-tetrahydrocannabinol causes enduring cognitive deficits associated with alteration of cortical gene expression and neurotransmission in rats. Addict Biol 12: 485-495. (Pubitemid 47196349)
9. Campolongo P, Trezza V, Ratano P, Palmery M, Cuomo V, (2011). Developmental consequences of perinatal cannabis exposure: behavioral and neuroendocrine effects in adult rodents. Psychopharmacology (Berl) 214: 5-15.
10. Clancy B, Darlington RB, Finlay BL, (2001). Translating developmental time across mammalian species. Neuroscience 105: 7-17. (Pubitemid 32722089)
11. Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR, et al. (2001). Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci U S A 98: 9371-9376. (Pubitemid 32743923)
12. Crawley JN, Paylor R, (1997). A proposed test battery and constellations of specific behavioral paradigms to investigate the behavioral phenotypes of transgenic and knockout mice. Horm Behav 31: 197-211. (Pubitemid 27305718)
13. De Pietri Tonelli D, Pulvers JN, Haffner C, Murchison EP, Hannon GJ, Huttner WB, (2008). miRNAs are essential for survival and differentiation of newborn neurons but not for expansion of neural progenitors during early neurogenesis in the mouse embryonic neocortex. Development 135: 3911-3921.
14. Deacon RM, Rawlins JN, (2006). T-maze alternation in the rodent. Nat Protoc 1: 7-12.
15. Diav-Citrin O, (2011). Prenatal exposures associated with neurodevelopmental delay and disabilities. Dev Disabil Res Rev 17: 71-84.
16. Diaz-Alonso J, Aguado T, Wu CS, Palazuelos J, Hofmann C, Garcez P, et al. (2012). The CB(1) cannabinoid receptor drives corticospinal motor neuron differentiation through the Ctip2/Satb2 transcriptional regulation axis. J Neurosci 32: 16651-16665.
17. Englund C, Fink A, Lau C, Pham D, Daza RA, Bulfone A, et al. (2005). Pax6, Tbr2, and Tbr1 are expressed sequentially by radial glia, intermediate progenitor cells, and postmitotic neurons in developing neocortex. J Neurosci 25: 247-251. (Pubitemid 40110787)
18. Freund TF, Katona I, Piomelli D, (2003). Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 83: 1017-1066. (Pubitemid 36828930)
19. Fried PA, Watkinson B, Gray R, (2003). Differential effects on cognitive functioning in 13- to 16-year-olds prenatally exposed to cigarettes and marihuana. Neurotoxicol Teratol 25: 427-436. (Pubitemid 36700422)
20. Gaffuri AL, Ladarre D, Lenkei Z, (2012). Type-1 cannabinoid receptor signaling in neuronal development. Pharmacology 90: 19-39.
21. Galve-Roperh I, Palazuelos J, Aguado T, Guzman M, (2009). The endocannabinoid system and the regulation of neural development: potential implications in psychiatric disorders. Eur Arch Psychiatry Clin Neurosci 259: 371-382.
22. Geyer MA, McIlwain KL, Paylor R, (2002). Mouse genetic models for prepulse inhibition: an early review. Mol Psychiatry 7: 1039-1053. (Pubitemid 36044262)
23. Guindon J, Lai Y, Takacs SM, Bradshaw HB, Hohmann AG, (2013). Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment. Pharmacol Res 67: 94-109.
24. Harkany T, Guzman M, Galve-Roperh I, Berghuis P, Devi LA, Mackie K, (2007). The emerging functions of endocannabinoid signaling during CNS development. Trends Pharmacol Sci 28: 83-92. (Pubitemid 46161836)
25. Harkany T, Keimpema E, Barabas K, Mulder J, (2008). Endocannabinoid functions controlling neuronal specification during brain development. Mol Cell Endocrinol 286 (1-2 Suppl 1): S84-S90.
26. Johnson DS, Ahn K, Kesten S, Lazerwith SE, Song Y, Morris M, et al. (2009). Benzothiophene piperazine and piperidine urea inhibitors of fatty acid amide hydrolase (FAAH). Bioorg Med Chem Lett 19: 2865-2869.
27. Jutras-Aswad D, DiNieri JA, Harkany T, Hurd YL, (2009). Neurobiological consequences of maternal cannabis on human fetal development and its neuropsychiatric outcome. Eur Arch Psychiatry Clin Neurosci 259: 395-412.
28. Kano M, Ohno-Shosaku T, Hashimotodani Y, Uchigashima M, Watanabe M, (2009). Endocannabinoid-mediated control of synaptic transmission. Physiol Rev 89: 309-380.
29. Katona I, Freund TF, (2008). Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat Med 14: 923-930.
30. Keimpema E, Mackie K, Harkany T, (2011). Molecular model of cannabis sensitivity in developing neuronal circuits. Trends Pharmacol Sci 32: 551-561.
31. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
32. Kohno M, Hasegawa H, Inoue A, Muraoka M, Miyazaki T, Oka K, et al. (2006). Identification of N-arachidonylglycine as the endogenous ligand for orphan G-protein-coupled receptor GPR18. Biochem Biophys Res Commun 347: 827-832. (Pubitemid 44109679)
33. Lichtman AH, Leung D, Shelton CC, Saghatelian A, Hardouin C, Boger DL, et al. (2004a). Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity. J Pharmacol Exp Ther 311: 441-448. (Pubitemid 39391527)
34. Lichtman AH, Shelton CC, Advani T, Cravatt BF, (2004b). Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia. Pain 109: 319-327. (Pubitemid 38638709)
35. Lo Verme J, Fu J, Astarita G, La Rana G, Russo R, Calignano A, et al. (2005). The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol 67: 15-19. (Pubitemid 40069962)
36. Long JZ, Nomura DK, Vann RE, Walentiny DM, Booker L, Jin X, et al. (2009). Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo. Proc Natl Acad Sci U S A 106: 20270-20275.
37. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
38. McHugh D, Hu SS, Rimmerman N, Juknat A, Vogel Z, Walker JM, et al. (2010). N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor. BMC Neurosci 11: 44.
39. Mackie K, (2006). Cannabinoid receptors as therapeutic targets. Annu Rev Pharmacol Toxicol 46: 101-122.
40. Mackie K, Stella N, (2006). Cannabinoid receptors and endocannabinoids: evidence for new players. AAPS J 8: E298-E306.
41. Mangieri RA, Piomelli D, (2007). Enhancement of endocannabinoid signaling and the pharmacotherapy of depression. Pharmacol Res 56: 360-366. (Pubitemid 350026393)
42. Marin-Padilla M, (1988). Early ontogenesis of the human cortex. In:, Peter A, Jones EG, (eds). Cerebral Cortex Vol. 7 Development and Maturation of the Cerebral Cortex. Plenum: New York, pp. 121-123.
43. Minnes S, Lang A, Singer L, (2011). Prenatal tobacco, marijuana, stimulant, and opiate exposure: outcomes and practice implications. Addict Sci Clin Pract 6: 57-70.
44. Mulder J, Aguado T, Keimpema E, Barabas K, Ballester Rosado CJ, Nguyen L, et al. (2008). Endocannabinoid signaling controls pyramidal cell specification and long-range axon patterning. Proc Natl Acad Sci U S A 105: 8760-8765. (Pubitemid 351987753)
45. Naidu PS, Varvel SA, Ahn K, Cravatt BF, Martin BR, Lichtman AH, (2007). Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality. Psychopharmacology (Berl) 192: 61-70. (Pubitemid 46673891)
46. Nomura DK, Morrison BE, Blankman JL, Long JZ, Kinsey SG, Marcondes MC, et al. (2011). Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science 334: 809-813.
47. Osei-Hyiaman D, Depetrillo M, Harvey-White J, Bannon AW, Cravatt BF, Kuhar MJ, et al. (2005). Cocaine- and amphetamine-related transcript is involved in the orexigenic effect of endogenous anandamide. Neuroendocrinology 81: 273-282. (Pubitemid 41397036)
48. Overton HA, Babbs AJ, Doel SM, Fyfe MC, Gardner LS, Griffin G, et al. (2006). Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab 3: 167-175.
49. Panlilio LV, Solinas M, Matthews SA, Goldberg SR, (2007). Previous exposure to THC alters the reinforcing efficacy and anxiety-related effects of cocaine in rats. Neuropsychopharmacology 32: 646-657.
50. Paylor R, Crawley JN, (1997). Inbred strain differences in prepulse inhibition of the mouse startle response. Psychopharmacology (Berl) 132: 169-180. (Pubitemid 27338992)
51. Peier AM, McIlwain KL, Kenneson A, Warren ST, Paylor R, Nelson DL, (2000). Over)correction of FMR1 deficiency with YAC transgenics: behavioral and physical features. Hum Mol Genet 9: 1145-1159. (Pubitemid 30248600)
52. Petit-Demouliere B, Chenu F, Bourin M, (2005). Forced swimming test in mice: a review of antidepressant activity. Psychopharmacology (Berl) 177: 245-255. (Pubitemid 40137284)
53. Piomelli D, (2003). The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 4: 873-884. (Pubitemid 37351427)
54. Piomelli D, Tarzia G, Duranti A, Tontini A, Mor M, Compton TR, et al. (2006). Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). CNS Drug Rev 12: 21-38. (Pubitemid 44133578)
55. Prus AJ, James JR, Rosecrans JA, (2009). Conditioned Place Preference.
56. Reisel D, Bannerman DM, Schmitt WB, Deacon RM, Flint J, Borchardt T, et al. (2002). Spatial memory dissociations in mice lacking GluR1. Nat Neurosci 5: 868-873. (Pubitemid 34976652)
57. Richardson GA, Day NL, Goldschmidt L, (1995). Prenatal alcohol, marijuana, and tobacco use: infant mental and motor development. Neurotoxicol Teratol 17: 479-487.
58. Rubio P, Rodriguez de Fonseca F, Martin-Calderon JL, Del Arco I, Bartolome S, Villanua MA, et al. (1998). Maternal exposure to low doses of delta9-tetrahydrocannabinol facilitates morphine-induced place conditioning in adult male offspring. Pharmacol Biochem Behav 61: 229-238. (Pubitemid 28498205)
59. Saghatelian A, McKinney MK, Bandell M, Patapoutian A, Cravatt BF, (2006). A FAAH-regulated class of N-acyl taurines that activates TRP ion channels. Biochemistry 45: 9007-9015. (Pubitemid 44156362)
60. Schneider M, (2009). Cannabis use in pregnancy and early life and its consequences: animal models. Eur Arch Psychiatry Clin Neurosci 259: 383-393.
61. Sciolino NR, Zhou W, Hohmann AG, (2011). Enhancement of endocannabinoid signaling with JZL184, an inhibitor of the 2-arachidonoylglycerol hydrolyzing enzyme monoacylglycerol lipase, produces anxiolytic effects under conditions of high environmental aversiveness in rats. Pharmacol Res 64: 226-234.
62. Sheskin T, Hanus L, Slager J, Vogel Z, Mechoulam R, (1997). Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor. J Med Chem 40: 659-667. (Pubitemid 27102571)
63. Singh ME, McGregor IS, Mallet PE, (2006). Perinatal exposure to delta(9)-tetrahydrocannabinol alters heroin-induced place conditioning and fos-immunoreactivity. Neuropsychopharmacology 31: 58-69. (Pubitemid 43250941)
64. Solinas M, Panlilio LV, Tanda G, Makriyannis A, Matthews SA, Goldberg SR, (2005). Cannabinoid agonists but not inhibitors of endogenous cannabinoid transport or metabolism enhance the reinforcing efficacy of heroin in rats. Neuropsychopharmacology 30: 2046-2057. (Pubitemid 43093504)
65. Tam J, Ofek O, Fride E, Ledent C, Gabet Y, Muller R, et al. (2006). Involvement of neuronal cannabinoid receptor CB1 in regulation of bone mass and bone remodeling. Mol Pharmacol 70: 786-792. (Pubitemid 44268435)
66. Trezza V, Campolongo P, Cassano T, Macheda T, Dipasquale P, Carratu MR, et al. (2008). Effects of perinatal exposure to delta-9-tetrahydrocannabinol on the emotional reactivity of the offspring: a longitudinal behavioral study in Wistar rats. Psychopharmacology (Berl) 198: 529-537.
67. Tritto T, McCallum SE, Waddle SA, Hutton SR, Paylor R, Collins AC, et al. (2004). Null mutant analysis of responses to nicotine: deletion of beta2 nicotinic acetylcholine receptor subunit but not alpha7 subunit reduces sensitivity to nicotine-induced locomotor depression and hypothermia. Nicotine Tob Res 6: 145-158.
68. Viveros MP, Llorente R, Suarez J, Llorente-Berzal A, Lopez-Gallardo M, de Fonseca FR, (2012). The endocannabinoid system in critical neurodevelopmental periods: sex differences and neuropsychiatric implications. J Psychopharmacol 26: 164-176.
69. Watanabe K, Matsunaga T, Nakamura S, Kimura T, Ho IK, Yoshimura H, et al. (1999). Pharmacological effects in mice of anandamide and its related fatty acid ethanolamides, and enhancement of cataleptogenic effect of anandamide by phenylmethylsulfonyl fluoride. Biol Pharm Bull 22: 366-370. (Pubitemid 29219978)
70. Wu CS, Zhu J, Wager-Miller J, Wang S, O'Leary D, Monory K, et al. (2010). Requirement of cannabinoid CB(1) receptors in cortical pyramidal neurons for appropriate development of corticothalamic and thalamocortical projections. Eur J Neurosci 32: 693-706.
71. Wu CS, Jew CP, Lu HC, (2011). Lasting impacts of prenatal cannabis exposure and the role of endogenous cannabinoids in the developing brain. Future Neurol 6: 459-480.
72. Zygmunt PM, Petersson J, Andersson DA, Chuang H, Sorgard M, Di Marzo V, et al. (1999). Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400: 452-457. (Pubitemid 29361798)